DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
AD1105503
Title:
Evaluation of Multiple Potential Pharmacogenomic Risk Factors for Chronic Mefloquine Neurotoxicity through the Establishment of a Drug Safety Registry
Corporate Author:
Uniformed Services University Bethesda United States
Report Date:
2020-06-01
Abstract:
The purpose of this study is to investigate possible pharmacogenomic risk factors for mefloquine neurotoxicity and potentially find markers that may differentiate between mefloquine toxicity and PTSD. This study is a pilot study powered to find large, clinically significant differences in genetic variants along with exploratory objectives aimed at looking for trends in symptom complexes, environmental interactions with various genetic markers and differences between mefloquine toxicity and PTSD. The subject population includes anyone with a mefloquine exposure history or diagnosis of PTSD without mefloquine exposure. The study is a cross-sectional case-control study. The protocol has been approved by the USUHS IRB and the business contract is currently being reviewed.
Descriptive Note:
Technical Report,22 May 2019,21 May 2020
Pages:
0008
Distribution Statement:
Approved For Public Release;
File Size:
0.56MB
